

26 March 2019

## Placement

EVE Investments Limited (“EVE”) (ASX:EVE), an ASX-listed health, nutrition and wellness investment company, advises that it has completed a placement to raise \$350,000 before costs at 0.6 cents per share to two existing investors that wanted to increase their shareholding.

The placement which was completed at a premium to the current share price will provide additional working capital to the Company, including the Meluka Health divisions, of which EVE has recently moved to 100% control (see release 25 February 2019). \$250,000 of the shares were issued to substantial strategic shareholder TRT Investment Group (“TRT”). TRT is the Australian subsidiary of Tianjin Tongrentang Group one of China’s oldest pharmaceutical and traditional chinese medicine (TCM) enterprises and has a well-developed, extensive distribution network throughout China.

### For further information:

Bill Fry  
Investment Director  
+ 61 8 6465 5500  
[billf@eveinvestments.com.au](mailto:billf@eveinvestments.com.au)

### About EVE Investments

EVE Investments invests in technology companies with a focus on the health and wellness sector. The Company’s investment strategy has a three-pronged approach.

1. To invest in businesses that are in the early growth phase with the aim to support their expansion programs.
2. To identify products that have unique properties and a global reach application.
3. Preference for natural organic products that have demonstrated medicinal benefits.

For further information, please visit [www.eveinvestments.com.au](http://www.eveinvestments.com.au) and follow us on Twitter [@EVEInvestments](https://twitter.com/EVEInvestments)